Investment analysts at BTIG Research began coverage on shares of Bruker (NASDAQ:BRKR) in a research report issued on Friday, Marketbeat.com reports. The firm set a “buy” rating and a $42.00 price target on the medical research company’s stock. BTIG Research’s target price indicates a potential upside of 16.70% from the stock’s current price.
A number of other equities analysts have also weighed in on the company. Zacks Investment Research lowered Bruker from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Citigroup increased their price target on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, November 3rd. Cowen reiterated a “hold” rating and issued a $29.00 price target on shares of Bruker in a research report on Friday, November 3rd. Bank of America upgraded Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective for the company in a research report on Friday, November 3rd. Finally, JPMorgan Chase & Co. upgraded Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price objective for the company in a research report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $32.38.
Bruker (NASDAQ BRKR) opened at $35.99 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. Bruker has a 1 year low of $21.68 and a 1 year high of $36.53. The firm has a market capitalization of $5,598.71, a price-to-earnings ratio of 30.76, a P/E/G ratio of 2.71 and a beta of 1.12.
Several institutional investors have recently made changes to their positions in BRKR. AJO LP acquired a new stake in shares of Bruker during the 2nd quarter valued at about $46,075,000. First Trust Advisors LP lifted its holdings in shares of Bruker by 1,689.7% during the 3rd quarter. First Trust Advisors LP now owns 502,159 shares of the medical research company’s stock valued at $14,939,000 after buying an additional 474,101 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Bruker by 292.8% during the 3rd quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock valued at $16,868,000 after buying an additional 422,660 shares during the last quarter. Koch Industries Inc. lifted its holdings in shares of Bruker by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after buying an additional 322,252 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Bruker during the 2nd quarter valued at about $6,806,000. Institutional investors and hedge funds own 65.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking and Market News and is owned by of American Banking and Market News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/07/bruker-brkr-now-covered-by-btig-research.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
